Emmanuel Antonarakis

About Emmanuel Antonarakis
  • Understanding resistance to new treatments for advanced, metastatic prostate cancer represents an unmet medical need.
  • Dr. Antonarakis is studying genetic variants of the target of these new medicines as one possible mechanism for resistance.
  • Understanding the genetic basis for resistance to Zytiga and Xtandi can lead to improved use of these treatments and should reveal new targets for treating these highly drug-resistant patients.

What this means to patients: Understanding mechanisms of resistance to Xtandi and Zytiga should lead to improved therapy for treatment-resistant patients with advanced, metastatic prostate cancer.


2013 Steve Wynn-PCF Young Investigator

Emmanuel Antonarakis, MD

Johns Hopkins University School of Medicine


Michael Carducci, MD and Jun Luo, PhD

Project Title:

Understanding mechanisms of response and resistance to abiraterone (Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer, by interrogation of tumor biopsies for androgen receptor splice variants.